CD274 and cancer: In cohort B, cancer treatment consisted of single anti-PD-1 or anti-PD-L1 antibodies in seven (63%) and three (27%) cases, respectively, and one (9%) patient received chemotherapy in combination with an anti-PD-1 antibody.